Safety of sotorasib and panitumumab in advanced KRAS p.G12C-mutated colorectal cancer

Share :
Published: 23 Sep 2021
Views: 1220
Dr Marwan Fakih - City of Hope Comprehensive Cancer Center, Duarte, USA

Dr Marwan Fakih speaks to ecancer in an online interview for the ESMO 2021 meeting about the CodeBreak 101 study.

He gives the background of the phase Ib study and explains that it aims to evaluate the combination of sotorasib, a KRASG12C inhibitor, and panitumumab, an EGFR inhibitor, in advanced KRAS p.G12C-mutated colorectal cancer.

Dr Fakih reports that results suggest that this combination was safe and tolerable, with adverse events consistent with what they expected. He concludes by discussing what they hope to discover when the data matures.